J
JAZZ PHARMACEUTICALS PLC
NASDAQ: JAZZ (Jazz Pharmaceuticals plc)
最近更新时间: 15小时之前176.53
-0.39 (-0.22%)
| 前收盘价格 | 176.92 |
| 收盘价格 | 176.46 |
| 成交量 | 257,132 |
| 平均成交量 (3个月) | 959,483 |
| 市值 | 10,726,865,920 |
| 预期市盈率 (P/E Forward) | 8.89 |
| 价格/销量 (P/S) | 2.65 |
| 股市价格/股市净资产 (P/B) | 2.76 |
| 52周波幅 | |
| 利润日期 | 5 Nov 2025 |
| 营业毛利率 | 11.86% |
| 营业利益率 (TTM) | -2.90% |
| 稀释每股收益 (EPS TTM) | 7.37 |
| 季度收入增长率 (YOY) | -0.50% |
| 季度盈利增长率 (YOY) | 103.00% |
| 总债务/股东权益 (D/E MRQ) | 129.82% |
| 流动比率 (MRQ) | 3.38 |
| 营业现金流 (OCF TTM) | 1.56 B |
| 杠杆自由现金流 (LFCF TTM) | 1.50 B |
| 资产报酬率 (ROA TTM) | 3.99% |
| 股东权益报酬率 (ROE TTM) | 12.25% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Jazz Pharmaceuticals plc | 看涨 | 看涨 |
AIStockmoo 评分
-0.3
| 分析师共识 | 1.5 |
| 内部交易活动 | -1.5 |
| 价格波动 | -3.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | -0.30 |
|
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 3.04% |
| 机构持股比例 | 101.22% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 247.00 (B of A Securities, 39.92%) | 购买 |
| 中 | 202.00 (14.43%) | |
| 低 | 155.00 (RBC Capital, -12.20%) | 购买 |
| 平均值 | 202.88 (14.93%) | |
| 总计 | 7 购买, 1 保留 | |
| 平均价格@调整类型 | 161.71 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| UBS | 24 Nov 2025 | 188.00 (6.50%) | 保留 | 180.90 |
| B of A Securities | 18 Nov 2025 | 247.00 (39.92%) | 购买 | 180.52 |
| Baird | 18 Nov 2025 | 209.00 (18.39%) | 购买 | 180.52 |
| Wells Fargo | 18 Nov 2025 | 235.00 (33.12%) | 购买 | 180.52 |
| Morgan Stanley | 17 Nov 2025 | 205.00 (16.13%) | 购买 | 170.09 |
| 20 Oct 2025 | 180.00 (1.97%) | 购买 | 134.85 | |
| RBC Capital | 06 Nov 2025 | 155.00 (-12.20%) | 购买 | 134.05 |
| JP Morgan | 27 Oct 2025 | 199.00 (12.73%) | 购买 | 139.33 |
| Goldman Sachs | 29 Aug 2025 | 185.00 (4.80%) | 购买 | 127.75 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| CARR PATRICIA | - | 180.52 | -5,319 | -960,186 |
| COZADD BRUCE C | 175.74 | 180.52 | -15,494 | -2,808,956 |
| HENDERSON MARY ELIZABETH | - | 176.08 | -1,331 | -234,362 |
| IANNONE ROBERT | - | 170.09 | -7,159 | -1,217,674 |
| MCSHARRY HEATHER ANN | - | 175.74 | -3,415 | -600,152 |
| WINNINGHAM RICK E | - | 180.52 | -5,500 | -992,860 |
| 累积净数量 | -38,218 | |||
| 累积净值 ($) | -6,814,190 | |||
| 累积平均购买 ($) | 175.74 | |||
| 累积平均卖出 ($) | 177.25 | |||
| 内部人员交易波幅 ($) | ||||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| COZADD BRUCE C | 董事 | 20 Nov 2025 | 获得 (+) | 2,506 | 175.74 | 440,404 |
| MCSHARRY HEATHER ANN | 董事 | 20 Nov 2025 | 卖 (-) | 3,415 | 175.74 | 600,152 |
| MCSHARRY HEATHER ANN | 董事 | 20 Nov 2025 | 执行期权 | 3,415 | - | - |
| HENDERSON MARY ELIZABETH | 职员 | 19 Nov 2025 | 处理 (-) | 1,331 | 176.08 | 234,362 |
| WINNINGHAM RICK E | 董事 | 18 Nov 2025 | 卖 (-) | 5,500 | 180.52 | 992,860 |
| CARR PATRICIA | 职员 | 18 Nov 2025 | 卖 (-) | 5,319 | 180.52 | 960,186 |
| CARR PATRICIA | 职员 | 18 Nov 2025 | 执行期权 | 5,250 | - | - |
| COZADD BRUCE C | 董事 | 18 Nov 2025 | 卖 (-) | 18,000 | 180.52 | 3,249,360 |
| IANNONE ROBERT | 职员 | 17 Nov 2025 | 自动卖出 (-) | 7,159 | 170.09 | 1,217,674 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合